Introduction by Croakey: Today marks four years since the first COVID-19 case was reported in Aotearoa/New Zealand.
Highlighting that COVID-complacency is not unique to Australia, public health and primary care academics in Aotearoa/New Zealand remind us that ignoring the pandemic “won’t make it go away”.
Professor Michael Baker and Associate Professor Amanda Kvalsvig at University of Otago and Associate Professor Matire Harwood at The University of Auckland argue below that an integrated respiratory infectious disease strategy – including vaccination, testing, self-isolation when sick and other public health measures – is needed to reduce the pandemic’s impact.
“In the face of this continuing pandemic threat, we need a response that is evidence-informed rather than evidence-ignored,” they write.
The article below was first published in The Conversation under the title, ‘A pandemic that won’t go away – as COVID enters its 5th year, NZ needs a realistic strategy’.
Michael Baker, Amanda Kvalsvig and Matire Harwood write:
February 28 marks four years since COVID-19 was first reported in Aotearoa/New Zealand. Many of us are probably surprised this virus is still causing a pandemic.
The World Health Organization refers to COVID-19 as a continuing pandemic. As Scientific American put it recently, it “has been the elephant in every room – sometimes confronted and sometimes ignored but always present”.
It wasn’t meant to be like this. The 1918 influenza pandemic swept through New Zealand in eight weeks, killing 9,000 people – almost one percent of the population. Then it was gone, returning as a new seasonal flu virus.
In doing so, it defined how pandemics were expected to behave. This model was written into pandemic plans and collective thinking across the globe.
But COVID is still circulating four years after New Zealand reported its first case, and more than two years after the Omicron variant arrived and infection became widespread.
Constantly present, it is also occurring in waves. Unexpectedly, the current fifth wave was larger than the fourth, suggesting we can’t rely on the comforting assumption that COVID will get less severe over time.
Unpredictable evolutionary shifts
These waves are driven by the interaction of the organism (SARS CoV-2 virus), the host (human characteristics such as immunity and behaviour), and environmental factors (such as indoor ventilation).
Continuing viral evolution is a major contributor to the changing dynamic. The virus has demonstrated an ability for large, unpredictable evolutionary shifts that dramatically alter its genome and spike protein.
The result is an enhanced ability to evade prior immunity and infect more people. This jump was seen with the highly mutated BA.2.86 subvariant in mid-2023.
Its offspring, JN.1, has acquired additional changes and is causing such a wave of new infections it could potentially be the next variant of concern, with its own Greek letter. It is now driving epidemic increases across the globe, including in Aotearoa/New Zealand.
This dominance by a single subvariant takes us back to the first year of Omicron in 2022.
Under-counting the pandemic impact
The pandemic continues to have a large, visible health impact. It is a leading cause of serious illness and death, mainly in older populations and those with existing long-term health conditions.
In 2023, it caused more than 12,000 hospitalisations and 1,000 deaths in Aotearoa/New Zealand.
But COVID-19 also has an important and largely unmeasured burden of disease as the cause of long COVID, which may become its biggest health impact. A growing number of studies are describing an estimated incidence of long COVID of five percent to 15 percent of all infections.
For example, a recent large study of almost 200,000 Scottish adults reported that, after adjustment for factors that might confuse the results, long COVID prevalence following an infection was 6.6 percent at six months, 6.5 percent at 12 months, and 10.4 percent at 18 months.
These findings illustrate an important feature of long COVID – recovery can take two years or more, with symptoms that fluctuate over time.
An integrated respiratory disease strategy
Aotearoa/New Zealand now needs a strong, integrated response to COVID-19 and other respiratory infections.
The major pandemic interventions have not changed – vaccination, public health and social measures to prevent infection, and antivirals for more vulnerable groups. The evidence has firmed up that long COVID risk is reduced by vaccination, but research is less certain for antivirals.
But growing pandemic complacency from political leaders and the public has changed things. Some of this apparent indifference can be put down to understandable fatigue with response measures. But it remains dangerous in the face of a continuing pandemic.
One way to keep a focus on prevention and control would be to include these measures in an integrated respiratory infectious disease strategy. This would combine COVID-19 control measures with those used to protect against influenza, respiratory syncytial virus (RSV), and other respiratory infections.
Measles could be added to the list, given the rising threat to New Zealand from a global resurgence of the disease.
This integrated strategy would include vaccination, promoting testing and self-isolation when sick, and measures to reduce transmission in critical indoor environments such as healthcare, public transport and education settings.
Such a programme would need to be supported with community engagement, education, surveillance and research.
Structural inequalities mean Māori, Pacific peoples, and those living in relative deprivation, are less vaccinated, less protected from infection, less tested and less likely to have antivirals.
Consequently, they are more likely to be hospitalised and die from COVID-19. These inequities are currently not being systematically tracked and acted on.
Ignoring it won’t make it go away
As we enter the fifth pandemic year, we need a change in thinking about COVID-19. This infection has pathological features in common with the other severe coronaviruses (SARS and MERS).
It is wishful thinking to imagine it will suddenly transform into a common cold coronavirus. As a recent review article concluded:
Transition from a pandemic to future endemic existence of SARS-CoV-2 is likely to be long and erratic […] endemic SARS-CoV-2 is by far not a synonym for safe infections, mild COVID-19 or a low population mortality and morbidity burden.”
In the face of this continuing pandemic threat, we need a response that is evidence-informed rather than evidence-ignored.
About the authors
Michael Baker is a Professor of Public Health at University of Otago, Amanda Kvalsvig is an Associate Professor in the Department of Public Health at University of Otago, and Matire Harwood is an Associate Professor in the Department of General Practice and Primary Care at University of Auckland, Waipapa Taumata Rau.
Baker is a member of the Ministry of Health’s COVID-19 Technical Advisory Group (TAG). The University of Otago receives funding from the Health Research Council of New Zealand and the New Zealand Ministry of Health for his research on COVID-19 and other infectious diseases.
Harwood was a member of the Ministry of Health COVID-19 TAG. Harwood receives research funding from Health Research Council, National Heart Foundation and National Science Challenge-Healthier Lives. She also works at Papakura Marae which received funding for COVID-19 testing, vaccination and management.
See Croakey’s archive of articles on COVID-19
